Ensysce Biosciences, Inc.ENSCNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank81
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P81
Within normal range
vs 2Y Ago
3.2x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 53.63% |
| Q2 2025 | 1.98% |
| Q1 2025 | -50.40% |
| Q4 2024 | 124.87% |
| Q3 2024 | 78.52% |
| Q2 2024 | 21.61% |
| Q1 2024 | -65.11% |
| Q4 2023 | 16.60% |
| Q3 2023 | 16.50% |
| Q2 2023 | -8.48% |
| Q1 2023 | -72.12% |
| Q4 2022 | 35.45% |
| Q3 2022 | -10.45% |
| Q2 2022 | 69.13% |
| Q1 2022 | 43.52% |
| Q4 2021 | 27.60% |
| Q3 2021 | 270.16% |
| Q2 2021 | 62.89% |
| Q1 2021 | -77.31% |
| Q4 2020 | 40.36% |
| Q3 2020 | -36.41% |
| Q2 2020 | 67.38% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |
| Q3 2019 | 0.00% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |
| Q4 2018 | 0.00% |
| Q3 2018 | 0.00% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |
| Q4 2017 | 0.00% |
| Q3 2017 | 0.00% |